Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.

Hdl Handle:
http://hdl.handle.net/10147/222411
Title:
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.
Authors:
D'Amico, Anthony V; Chen, Ming-Hui; Crook, Juanita; Armstrong, John G; Malone, Shawn; Steigler, Allison; Dunne, Mary; Kantoff, Philip W; Denham, James W
Affiliation:
Brigham and Women's Hospital, Boston, MA 02115, USA. adamico@partners.org
Citation:
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. 2011, 29 (35):4682-7 J. Clin. Oncol.
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue Date:
10-Dec-2011
URI:
http://hdl.handle.net/10147/222411
DOI:
10.1200/JCO.2011.37.0726
PubMed ID:
22042952
Abstract:
We evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories.
Item Type:
Article
Language:
en
MeSH:
Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cohort Studies; Combined Modality Therapy; Humans; Male; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Treatment Outcome
ISSN:
1527-7755

Full metadata record

DC FieldValue Language
dc.contributor.authorD'Amico, Anthony Ven_GB
dc.contributor.authorChen, Ming-Huien_GB
dc.contributor.authorCrook, Juanitaen_GB
dc.contributor.authorArmstrong, John Gen_GB
dc.contributor.authorMalone, Shawnen_GB
dc.contributor.authorSteigler, Allisonen_GB
dc.contributor.authorDunne, Maryen_GB
dc.contributor.authorKantoff, Philip Wen_GB
dc.contributor.authorDenham, James Wen_GB
dc.date.accessioned2012-05-08T11:08:38Z-
dc.date.available2012-05-08T11:08:38Z-
dc.date.issued2011-12-10-
dc.identifier.citationDuration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. 2011, 29 (35):4682-7 J. Clin. Oncol.en_GB
dc.identifier.issn1527-7755-
dc.identifier.pmid22042952-
dc.identifier.doi10.1200/JCO.2011.37.0726-
dc.identifier.urihttp://hdl.handle.net/10147/222411-
dc.description.abstractWe evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subject.meshAged-
dc.subject.meshAndrogen Antagonists-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshCohort Studies-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPrognosis-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshTreatment Outcome-
dc.titleDuration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.en_GB
dc.typeArticleen
dc.contributor.departmentBrigham and Women's Hospital, Boston, MA 02115, USA. adamico@partners.orgen_GB
dc.identifier.journalJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.description.provinceLeinsteren
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.